AVEO Pharmaceuticals, Inc. (AVEO) Given Consensus Recommendation of “Buy” by Brokerages

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has earned a consensus recommendation of “Buy” from the eight analysts that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $4.38.

Several research firms have weighed in on AVEO. Zacks Investment Research lowered AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, December 6th. began coverage on AVEO Pharmaceuticals in a research note on Wednesday, November 15th. They set a “buy” rating and a $5.00 price objective on the stock. B. Riley began coverage on AVEO Pharmaceuticals in a research note on Monday, November 13th. They set a “buy” rating and a $5.00 price objective on the stock. Seaport Global Securities reaffirmed a “buy” rating on shares of AVEO Pharmaceuticals in a research note on Friday, October 6th. Finally, Piper Jaffray Companies increased their price objective on AVEO Pharmaceuticals from $3.80 to $4.50 and gave the company an “overweight” rating in a research note on Monday, August 28th.

Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) opened at $2.95 on Wednesday. The company has a quick ratio of 2.33, a current ratio of 2.33 and a debt-to-equity ratio of -0.32. AVEO Pharmaceuticals has a twelve month low of $0.50 and a twelve month high of $4.24.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Victory Capital Management Inc. acquired a new stake in shares of AVEO Pharmaceuticals during the third quarter valued at $164,000. Fore Research & Management LP acquired a new stake in shares of AVEO Pharmaceuticals during the second quarter valued at $111,000. Rehmann Capital Advisory Group acquired a new stake in shares of AVEO Pharmaceuticals during the third quarter valued at $193,000. OxFORD Asset Management LLP acquired a new stake in shares of AVEO Pharmaceuticals during the third quarter valued at $228,000. Finally, Cannell Peter B & Co. Inc. boosted its stake in shares of AVEO Pharmaceuticals by 22.9% during the second quarter. Cannell Peter B & Co. Inc. now owns 109,875 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 20,500 shares during the last quarter. 50.91% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “AVEO Pharmaceuticals, Inc. (AVEO) Given Consensus Recommendation of “Buy” by Brokerages” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://stocknewstimes.com/2018/01/11/aveo-pharmaceuticals-inc-aveo-given-consensus-recommendation-of-buy-by-brokerages.html.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply